Randomized trial of cisplatin and carboplatin versus cisplatin, vinblastine and bleomycin in ovarian cancer

Citation
F. Kikkawa et al., Randomized trial of cisplatin and carboplatin versus cisplatin, vinblastine and bleomycin in ovarian cancer, GYNECOL OBS, 50(4), 2000, pp. 269-274
Citations number
21
Language
INGLESE
art.tipo
Article
Categorie Soggetti
da verificare
Journal title
GYNECOLOGIC AND OBSTETRIC INVESTIGATION
ISSN journal
0378-7346 → ACNP
Volume
50
Issue
4
Year of publication
2000
Pages
269 - 274
Database
ISI
SICI code
0378-7346(2000)50:4<269:RTOCAC>2.0.ZU;2-9
Abstract
Between January 1992 and July 1997, 202 cases of epithelial ovarian cancer were registered and assigned randomly to a combination of cisplatin and car boplatin (PP group), or cisplatin, vinblastine and bleomycin (PVB group). W e analyzed 189 patients whose clinical records were available. The PP chemo therapeutic regimen was advantageous in terms of overall survival compared to the PVB regimen until 4 years after the initial operation. However, the 5-year survival rates were almost the same in both groups. However, in stag e ill patients, the mean survival time in the PP group was 51.4 months and that in the PVB group was 23.3 months, and there was a statistically signif icant difference in the survival curves between the two groups (p = 0.0158) . The 5-year survival rates were 31.1 and 20.4% in the PP and PVB groups, r espectively, in stage III patients. The PP regimen was also significantly s uperior in patients with macroscopic residual tumor after the initial opera tion, and the 5-year survival rates were 25.7 and 10.1% in the PP and PVB g roups, respectively (p = 0.0128). However, there was no significant differe nce between the two regimens in patients without macroscopic residual tumor . Cox's proportional hazards regression analysis showed that tumor stage, p resence of macroscopic residual tumor, and the chemotherapeutic regimen use d were significant prognostic factors. In conclusion, the PP chemotherapeut ic regimen is superior to the PVB regimen especially in the treatment of ad vanced ovarian cancer. Copyright (C) 2000 S. Karger AG, Basel.